E. Heidemann

Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)

Georg Lenz, Martin Dreyling, Eva Hoster et al. · Journal of Clinical Oncology · 2005 · 573 citations · Full text

Randomized phase II study of single-agent epirubicin +/— verapamil in patients with advanced metastatic breast cancer

K. Mross, Lutz Edler, W. Jonat et al. · Annals of Oncology · 1993 · 51 citations

Breast Oncology, Oncology, Medicine +7

Is first-line single-agent mitoxantrone in the treatment ofhigh-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial

E. Heidemann, Herbert Stoeger, Rainer Souchon et al. · Annals of Oncology · 2002 · 49 citations

Breast Oncology, Oncology, Combination Chemotherapy +9

Primary breast cancer therapy in six regions of Germany

Jutta Engel, Gabriele Nagel, Eun‐Kyoung Breuer et al. · European Journal of Cancer · 2002 · 46 citations

Breast Oncology, Medicine, Cancer Management +3

Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial).

Hermann Einsele, Peter Liebisch, Christian Langer et al. · Blood · 2009 · 43 citations